4-Hydroxynonenal promotes growth and angiogenesis of breast cancer cells through HIF-1α stabilization

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 23, 2014, Pages 10151-10156

  Li, Yao Ping ^a   Tian, Fu Guo ^a   Shi, Peng Cheng ^a   Guo, Ling Yun ^a   Wu, Hai Ming ^a   Chen, Run Qi ^a   Xue, Jin Ming ^a  

^a Shanxi Cancer Hospital   (China)

Author keywords

4 Hydroxynonenal; Angiogenesis; Breast cancer; Growth; HIF 1 ; Invasion; SIRT3; VEGF

Indexed keywords

4-HYDROXY-2-NONENAL; ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SIRT3 PROTEIN, HUMAN; SIRTUIN 3; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE SILENCING; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ALDEHYDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MCF-7 CELLS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SIRTUIN 3; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921787879     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10151     Document Type: Article

References (36)

1. Ahn GO, Seita J, Hong BJ, et al (2014). Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci U S A, 111, 2698-703.
2. Ayala A, Munoz MF, Arguelles S (2014). Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev, 2014, 360438.
3. Bennaars-Eiden A, Higgins L, Hertzel AV, et al (2002). Covalent modification of epithelial fatty acid-binding protein by 4-hydroxynonenal in vitro and in vivo. Evidence for a role in antioxidant biology. J Biol Chem, 277, 50693-702.
4. Caito S, Rajendrasozhan S, Cook S, et al (2010). SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J, 24, 3145-59.
5. Cao ZG, Xu X, Xue YM,Zhao SL (2014). Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145. Contemp Oncol (Pozn), 18, 22-8.
6. Chen Y, Fu LL, Wen X, et al (2014). Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis, 5, 1047.
7. Christov PP, Hawkins EK, Kett NR, et al (2013). Simplified synthesis of individual stereoisomers of the 4-hydroxynonenal adducts of deoxyguanosine. Tetrahedron Lett, 54, 4289-91.
8. Dalleau S, Baradat M, Gueraud F, et al (2013). Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ, 20, 1615-30.
9. Finley LW, Carracedo A, Lee J, et al (2011). SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell, 19, 416-28.
10. Fritz KS, Galligan JJ, Smathers RL, et al (2011). 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol, 24, 651-62.
11. Groulx I, Lee S (2002). Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol, 22, 5319-36.
12. Jin H, Zangar RC (2009). Protein modifications as potential biomarkers in breast cancer. Biomark Insights, 4, 191-200.
13. Ke Q, Costa M (2006). Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol, 70, 1469-80.
14. Kim JW, Tchernyshyov I, Semenza GL, et al (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 3, 177-85 .
15. Lee S, Chen TT, Barber CL, et al (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell, 130, 691-703.
16. Li DW, Dong P, Wang F, et al (2013). Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1 alpha. Asian Pac J Cancer Prev, 14, 4853-8.
17. Lopez-Lazaro M (2006). HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB J, 20, 828-32.
18. Macpherson LJ, Xiao B, Kwan KY, et al (2007). An ion channel essential for sensing chemical damage. J Neurosci, 27, 11412-5.
19. Maxwell PH, Wiesener MS, Chang GW, et al (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-5.
20. Park JH, Kim TY, Jong HS, et al (2003). Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res, 9, 433-40.
21. Patrick B, Li J, Jeyabal PV, et al (2005). Depletion of 4-hydroxynonenal in hGSTA4-transfected HLE B-3 cells results in profound changes in gene expression. Biochem Biophys Res Commun, 334, 425-32.
22. Pugh CW, Ratcliffe PJ (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9, 677-84.
23. Ryan BJ, Nissim A, Winyard PG (2014). Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol, 2, 715-24.
24. Sharma R, Sharma A, Dwivedi S, et al (2008). 4-Hydroxynonenal self-limits fas-mediated DISC-independent apoptosis by promoting export of Daxx from the nucleus to the cytosol and its binding to Fas. Biochemistry, 47, 143-56.
25. Sharma R, Sharma A, Chaudhary P, et al (2012). Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane. Free Radic Biol Med, 52, 2177-85.
26. Shearn CT, Fritz KS, Reigan P, et al (2011a). Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells. Biochemistry, 50, 3984-96.
27. Shearn CT, Smathers RL, Stewart BJ, et al (2011b). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibition by 4-hydroxynonenal leads to increased Akt activation in hepatocytes. Mol Pharmacol, 79, 941-52.
28. Sovic A, Borovic S, Loncaric I, et al (2001). The carcinostatic and proapoptotic potential of 4-hydroxynonenal in HeLa cells is associated with its conjugation to cellular proteins. Anticancer Res, 21, 1997-2004.
29. Stroka DM, Burkhardt T, Desbaillets I, et al (2001). HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J, 15, 2445-53.
30. Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-34.
31. Ulrich HD (2007). SUMO teams up with ubiquitin to manage hypoxia. Cell, 131, 446-7.
32. Usatyuk PV, Natarajan V (2012). Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res, 83, 45-55.
33. van Hagen M, Overmeer RM, Abolvardi SS, et al (2010). RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha. Nucleic Acids Res, 38, 1922-31.
34. Vatsyayan R, Lelsani PC, Chaudhary P, et al (2012). The expression and function of vascular endothelial growth factor in retinal pigment epithelial (RPE) cells is regulated by 4-hydroxynonenal (HNE) and glutathione S-transferaseA4-4. Biochem Biophys Res Commun, 417, 346-51.
35. Xu N, Lei Z, Li XL, et al (2013). Clinical study of tumor angiogenesis and perfusion imaging using multi-slice spiral computed tomography for breast cancer. Asian Pac J Cancer Prev, 14, 429-33.
36. Zhu K, Jiao H, Li S, et al (2013). ATF4 promotes bone angiogenesis by increasing VEGF expression and release in the bone environment. J Bone Miner Res, 28, 1870-8